Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NCInternational journal of nanomedicine

Nanodelivery of Brucine in Myocardial Ischemia-Reperfusion Injury: Mitochondrial PANoptosis, Cardiotoxicity, and Translational Barriers.

  • Yi Guo1
  • Rui Bao1
  • Yuzhu Fu1
  • Yanfei Meng1
  • Lihong Zhang2
  • Yuling An3
  • Xiaoqi Wang4
4 affiliations
  1. 1Department of Surgical Intensive Care Unit, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences; Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, Yunnan Province, People's Republic of China.
  2. 2Department of Intensive Care Unit, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences; Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, Yunnan Province, People's Republic of China.
  3. 3Department of Surgical Intensive Care Unit, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, People's Republic of China.
  4. 4Department of Cardiac Surgery, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences; Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, Yunnan Province, People's Republic of China.
Read full textPDFDOICite

Abstract

Myocardial ischemia-reperfusion injury remains a major unresolved component of infarct expansion after timely restoration of coronary blood flow. Brucine, a toxic alkaloid from Strychnos nux-vomica L. is an instructive but experimentally constrained case study because low-exposure cardioprotective signals coexist with cardiac ion-channel liability and uncertain clinical dosing. This Review evaluates whether nanodelivery could widen the therapeutic window of brucine by reducing circulating free drug, enriching exposure near injured myocardium and enabling mechanistic testing of mitochondrial quality control, regulated cell death and antioxidant repair. The evidence base is mapped across direct brucine cardiovascular studies, direct brucine toxicology, brucine formulation studies outside cardiac reperfusion, non-brucine cardiac nanomedicine and general material-design principles. We emphasize that brucine-loaded nanomedicine has not yet been validated as a therapy for myocardial ischemia-reperfusion injury; progress will require direct formulation-specific pharmacokinetics, myocardial biodistribution, hERG/QT safety, arrhythmia monitoring, large-animal efficacy and manufacturing-quality evidence.

Related

  1. Statement of Retraction: Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway.
    Pharmaceutical biologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCDOAJ
  2. Myocardial Ischemia-Reperfusion Injury: Molecular Mechanisms and Innovative Therapeutic Strategies
    Dong Zhang, Xiaoting Yang, Shengyu Gong +4
    Reviews in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  3. AN INTEGRATED HEART-ON-A-CHIP NAM RESOLVES DISTINCT CLINICAL PHENOTYPES OF MYOCARDIAL ISCHEMIA-REPERFUSION INJURY
    K. Tran, A. R. Vincent, C. S. Whitmer +2
    bioRxivPreprintAll rights reservedFull textPhysiologybioRxiv
  4. Arsenic trioxide-induced cardiotoxicity: insights into the oxidative stress-inflammation positive feedback loop, translational biomarkers and targeted cardioprotective strategies— a narrative review
    Haiyan Wu, Jian Lv, Xiaoyang Hu
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textCardiovascular medicinePMCCrossrefEurope PMC
  5. Cardiac unloading via a transvalvular pump prevents arrhythmias following myocardial ischemia / reperfusion by preserving coronary microcirculation and cardiomyocyte nanostructure
    M. Ammon, P. H. Melo, K. Nowak +8
    bioRxivPreprintAll rights reservedFull textPhysiologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{guo2026nanodelivery,
  title = {{Nanodelivery of Brucine in Myocardial Ischemia-Reperfusion Injury: Mitochondrial PANoptosis, Cardiotoxicity, and Translational Barriers.}},
  author = {Yi Guo and Rui Bao and Yuzhu Fu and Yanfei Meng and Lihong Zhang and Yuling An and Xiaoqi Wang},
  journal = {International journal of nanomedicine},
  year = {2026},
  month = oct,
  doi = {10.2147/ijn.s616055},
  url = {https://europepmc.org/article/MED/42928913},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Nanodelivery of Brucine in Myocardial Ischemia-Reperfusion Injury: Mitochondrial PANoptosis, Cardiotoxicity, and Translational Barriers.
AU  - Yi Guo
AU  - Rui Bao
AU  - Yuzhu Fu
AU  - Yanfei Meng
AU  - Lihong Zhang
AU  - Yuling An
AU  - Xiaoqi Wang
PY  - 2026
DA  - 2026/10/21
JO  - International journal of nanomedicine
DO  - 10.2147/ijn.s616055
UR  - https://europepmc.org/article/MED/42928913
AB  - Myocardial ischemia-reperfusion injury remains a major unresolved component of infarct expansion after timely restoration of coronary blood flow. Brucine, a toxic alkaloid from Strychnos nux-vomica L. is an instructive but experimentally constrained case study because low-exposure cardioprotective signals coexist with cardiac ion-channel liability and uncertain clinical dosing. This Review evaluates whether nanodelivery could widen the therapeutic window of brucine by reducing circulating free drug, enriching exposure near injured myocardium and enabling mechanistic testing of mitochondrial quality control, regulated cell death and antioxidant repair. The evidence base is mapped across direct brucine cardiovascular studies, direct brucine toxicology, brucine formulation studies outside cardiac reperfusion, non-brucine cardiac nanomedicine and general material-design principles. We emphasize that brucine-loaded nanomedicine has not yet been validated as a therapy for myocardial ischemia-reperfusion injury; progress will require direct formulation-specific pharmacokinetics, myocardial biodistribution, hERG/QT safety, arrhythmia monitoring, large-animal efficacy and manufacturing-quality evidence.
SN  - 1176-9114
SN  - 1178-2013
ER  -